Lonza Cuts Guidance on Lower Demand
Wall Street Journal
Lonza lowered its sales target and core Ebitda margin for 2023, as current market dynamics are hurting demand for early-stage services and nutraceutical capsules.
Understanding current events through the lenses of the past and future.
Wall Street Journal
Lonza lowered its sales target and core Ebitda margin for 2023, as current market dynamics are hurting demand for early-stage services and nutraceutical capsules.